RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04973306, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically-confirmed esophageal squamous cell carcinoma and whose tissue samples were taken before treatment;

    Inclusion criterion 1

  3. Pre-treatment stage as clinical II-III (AJCC/UICC 8th Edition)

    Inclusion criterion 3

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and expected survival time ≥12 months;

    Inclusion criterion 5

  5. Patients with active infection of immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); HIV seropositivity; HBV DNA or HCV RNA positive;

    Exclusion criterion 11

  6. Pregnant or lactating women and fertile women who will not be using contraception during the trial;

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04973306, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically-confirmed esophageal squamous cell carcinoma and whose tissue samples were taken before treatment;
  • Tumors of the esophagus are located in the thoracic cavity;
  • Pre-treatment stage as clinical II-III (AJCC/UICC 8th Edition)
  • Age is between 18 years and 75 years;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and expected survival time ≥12 months;
  • Adequate cardiac function. All patients should perform ECG, and those with a cardiac history or ECG abnormality should perform echocardiography with the left ventricular ejection fraction > 50 %;
  • Adequate respiratory function with FEV1≥1.2L, FEV1%≥50% and DLCO≥50% shown in pulmonary function tests ;
  • Adequate bone marrow function (White Blood Cells >4x10\^9 /L; Neutrophil >2.0×10\^9 /L; Hemoglobin > 90 g/L; platelets>100x10\^9 /L);
  • Adequate liver function (Total bilirubin <1.5x Upper Level of Normal (ULN); Aspartate transaminase(AST) and Alanine transaminase (ALT) <1.5x ULN);
  • Adequate renal function (Glomerular filtration rate (CCr) >60 ml/min; serum creatinine (SCr) ≤120 µmol/L);
  • The patient has provided written informed consent and is able to understand and comply with the study;

Exclusion Criteria:

Exclusion Criteria associated with Cancer:

  • Patients with histological non-squamous cell carcinoma;
  • Patients with advanced non-operable or metastatic esophageal cancer;
  • Pre-treatment stage as cM+, cN3 or cT4b(non-curatively-resectable verified by the local surgical investigator, AJCC/UICC 8th Edition) or cTis-1a, cT1bN0;
  • Patients with another previous or current malignant disease which is likely to interfere with treatment or the assessment of response in the judgement of the local surgical investigator;
  • Patients who have received or are receiving other chemotherapy, radiotherapy or targeted therapy;

Other Exclusion Criteria:

  • Patients with autoimmune diseases history;
  • Recently or currently taking Glucocorticoids or Immunosuppressants;
  • Patients who underwent immunotherapy in the past;
  • Allergy to any antibody drugs or allergy to Paclitaxel and Carboplatin.
  • Past or currently suffering from chronic or recurrent autoimmune diseases;
  • Patients with active infection of immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); HIV seropositivity; HBV DNA or HCV RNA positive;
  • Patients with organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation);
  • Patients with severe systematic intercurrent disease, such as active infection or poorly controlled diabetes; coagulation disorders; hemorrhagic tendency or under treatment of thrombolysis or anticoagulant therapy;
  • Any patient with a significant medical condition which is thought unlikely to tolerate the therapies. Such as cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months), clinically-significant lung disease, clinically-significant bone marrow, liver, renal function disorder;
  • Pregnant or lactating women and fertile women who will not be using contraception during the trial;
  • Participation in another intervention clinical trial with interference to the chemotherapeutic or chemoradiotherapeutic intervention during this study or during the last 30 days prior to informed consent;
  • Expected lack of compliance with the protocol.

Quoted from ClinicalTrials.gov, NCT04973306, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04973306, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04973306